[Clinical evaluation of imipenem/cilastatin sodium against infections in compromised children (malignancy, hematological disease, collagen disease)].
Eighteen immuno-compromised children (malignancies, hematological diseases, collagen diseases) with neutropenia and infections were treated with imipenem/cilastatin sodium (IPM/CS), and the efficacy and the safety of the drug were evaluated. 1. Responses to IPM/CS were excellent in 13 patients, good in 1, and fair in 4. None of the patients displayed a poor response to the treatment thus the efficacy rate was 77.8%. 2. Of 5 patients with sepsis, 4 had excellent or good responses. IPM/CS was effective against sepsis caused by Enterococcus faecalis and Pseudomonas aeruginosa. 3. In patients with severe neutropenia (WBC less than 100/mm3), the efficacy rate was 70%. 4. As for side effects, elevations of GOT and GPT were observed in 1 patient with liver cirrhosis. These results indicate that IPM/CS is safe and effective in immuno-compromised children with neutropenia and infections.
Nakano
T
T
Department of Pediatrics, School of Medicine, Mie University.
Itoh
M
M
Sakurai
M
M
D000293:Adolescent; D000367:Age Factors; D001424:Bacterial Infections / Q000150:complications / Q000188:drug therapy*; D002648:Child; D002675:Child, Preschool; D015377:Cilastatin / Q000627:therapeutic use*; D003095:Collagen Diseases / Q000150:complications; D004359:Drug Therapy, Combination / Q000627:therapeutic use*; D005260:Female; D006402:Hematologic Diseases / Q000150:complications; D006801:Humans; D015378:Imipenem / Q000627:therapeutic use*; D016867:Immunocompromised Host; D007223:Infant; D008297:Male; D009369:Neoplasms / Q000150:complications; D009503:Neutropenia / Q000209:etiology; D009894:Opportunistic Infections / Q000150:complications / Q000188:drug therapy*
D015377:Cilastatin; D015378:Imipenem